1 Dec 2016 17:27
Motif Bio plc
("Motif Bio" or the "Company")
Issue of Equity and Total Voting Rights
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 119,990 new ordinary shares in the Company ("Ordinary Shares") as a result of the exercise of options.
Application has been made for the 119,990 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 6 December 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 180,763,734 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc | info@motifbio.com | |
Graham Lumsden (Chief Executive Officer) |
| |
|
| |
Zeus Capital Limited (NOMAD & BROKER) | +44 (0)20 3829 5000 | |
Phil Walker/Giles Balleny |
| |
Dominic Wilson |
| |
|
| |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6625 | |
Patrick Claridge/ David Hignell |
| |
John Howes/ Rob Rees (Broking) |
| |
|
| |
Walbrook PR Ltd. (FINANCIAL PR & IR) | +44 (0) 20 7933 8780 or motifbio@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Mike Wort | Mob: +44 (0)7900 608 002 | |
|
| |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
Raimund Gabriel |
| |
MTFB.L (MTFB)